vWF cleaving protease activity and inhibitors in patients with thrombotic thrombocytopenic purpura (TTP) treated with INTERCEPT FFP vs. conventional FFP: results of a phase III trial

Cerus Corporation, Concord, CA. (maureen_conlan@ceruscorp.com)

Transfusion. 2005;45((s3):):30A.. Abstract No. S92-040G.
Study details